RANI THERAPEUTICS HOLDINGS, INC.
Climate Impact & Sustainability Data (2023)
Reporting Period: 2023
Environmental Metrics
Social Achievements
- Reduction in workforce by approximately 25% as part of a restructuring plan to streamline operations and focus on key priorities.
Climate Goals & Targets
Short-term Goals:
- Initiate Phase 2 clinical trial of RT-102 in 2024.
- Initiate clinical testing of the RaniPill HC in the second half of 2024.
Environmental Challenges
- Substantial doubt regarding the ability to continue as a going concern due to insufficient cash resources to fund operations and pivotal clinical trials.
- Significant operating losses since inception and expectation of continued losses in the foreseeable future.
- Limited clinical data on product candidates for long-term use in humans.
- Intense competition in the biotherapeutics and pharmaceutical industries.
- Dependence on third-party suppliers for key materials and APIs.
- Risks associated with novel technologies and regulatory uncertainties.
- Challenges in patient enrollment and retention in clinical trials.
- Potential for product liability lawsuits.
- Stringent and evolving data privacy and security regulations.
- Risks related to intellectual property protection and enforcement.
- Potential for disruptions from catastrophic events and public health crises.
Mitigation Strategies
- Strategic program prioritization, expansion of manufacturing, and cost reduction initiatives (including workforce reduction).
- Seeking additional funding to support operations and clinical trials.
- Active management of costs and resources.
- Pursuing strategic partnerships to expand commercial reach.
- Investing in RaniPill capsule capabilities and intellectual property portfolio.
- Developing and implementing robust data privacy and security measures.
- Maintaining clinical trial liability insurance.
- Developing disaster recovery and business continuity plans.